Clinical Trials · NCT06049329
A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 36
- Start date
- Sep 2023
- Locations
- 1 site, Japan
- Primary endpoint
- Number of treatment emergent adverse events (TEAE)